Algert Global LLC Adverum Biotechnologies, Inc. Transaction History

Algert Global LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.81 - $1.34 $111,763 - $184,893	-137,980 Reduced 54.18%	116,685 $140,000
Q1 2022 May 16, 2022	BUY	$1.23 - $1.95 $113,430 - $179,829	92,220 Added 56.77%	254,665 $334,000
Q4 2021 Feb 14, 2022	SELL	$1.74 - $2.4 $120,138 - $165,708	-69,045 Reduced 29.83%	162,445 $286,000
Q3 2021 Nov 15, 2021	BUY	$2.08 - $3.6 $310,637 - $537,642	149,345 Added 181.81%	231,490 $502,000
Q2 2021 Aug 13, 2021	BUY	$3.36 - $10.56 $33,768 - $106,128	10,050 Added 13.94%	82,145 $288,000
Q1 2021 May 14, 2021	SELL	$9.26 - $14.36 $514,531 - $797,913	-55,565 Reduced 43.53%	72,095 $711,000
Q4 2020 Feb 12, 2021	BUY	$9.84 - $14.26 $362,013 - $524,625	36,790 Added 40.49%	127,660 $1.38 Million
Q3 2020 Nov 16, 2020	BUY	$10.3 - $21.64 $627,682 - $1.32 Million	60,940 Added 203.61%	90,870 $936,000
Q1 2020 May 13, 2020	BUY	$7.98 - $16.32 $238,841 - $488,457	29,930 New	29,930 $292,000
Q3 2019 Nov 14, 2019	SELL	$5.24 - $15.89 $132,886 - $402,970	-25,360 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$5.1 - $11.89 $129,335 - $301,530	25,360 New	25,360 $302,000
Q1 2019 May 01, 2019	SELL	$3.03 - $6.02 $285,162 - $566,560	-94,113 Closed	0 $0
Q4 2018 Feb 01, 2019	BUY	$2.87 - $5.92 $42,054 - $86,745	14,653 Added 18.44%	94,113 $296,000
Q3 2018 Nov 14, 2018	SELL	$4.5 - $7.6 $12,825 - $21,660	-2,850 Reduced 3.46%	79,460 $481,000
Q2 2018 Aug 02, 2018	BUY	$5.3 - $6.9 $49,449 - $64,377	9,330 Added 12.78%	82,310 $436,000
Q1 2018 May 03, 2018	BUY	$3.65 - $7.95 $266,377 - $580,191	72,980 New	72,980 $423,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $681M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

Stay updated on Algert Global LLC with notifications on news.